Zakrzewski Joseph S 4
4 · AN2 Therapeutics, Inc. · Filed Mar 31, 2022
Insider Transaction Report
Form 4
Zakrzewski Joseph S
Director
Transactions
- Conversion
Common Stock
2022-03-29+98,199→ 98,199 total - Conversion
Series A Convertible Preferred Stock
2022-03-29−98,199→ 0 total→ Common Stock (98,199 underlying)
Footnotes (1)
- [F1]Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.